Clinical developments of chemotherapeutic nanomedicines: Polymers and liposomes for delivery of camptothecins and platinum (II) drugs

Heidi M. Kieler-Ferguson, Jean Frechet, Francis C. Szoka

Research output: Contribution to journalArticlepeer-review

46 Citations (SciVal)

Abstract

For the past 40 years, liposomal and polymeric delivery vehicles have been studied as systems capable of modulating the cytotoxicity of small molecule chemotherapeutics, increasing tumor bearing animal survival times, and improving drug targeting. Although a number of macromolecular-drug conjugates have progressed to clinical trials, tuning drug release to maintain efficacy in conjunction with controlling drug toxicity has prevented the clinical adoption of many vehicles. In this article, we review the motivations for and approaches to polymer and liposomal delivery with regard to camptothecin and cisplatin delivery. WIREs Nanomed Nanobiotechnol 2013, 5:130-138. doi: 10.1002/wnan.1209 For further resources related to this article, please visit the WIREs website. Conflict of interest: Drs Kieler-Ferguson and Fréchet declare no conflicts of interest. Dr Szoka is the founder of a liposome drug delivery company that is not working on any of the compounds mentioned in this article. © 2013 Wiley Periodicals, Inc.
Original languageEnglish (US)
Pages (from-to)130-138
Number of pages9
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Volume5
Issue number2
DOIs
StatePublished - Jan 17 2013

Fingerprint

Dive into the research topics of 'Clinical developments of chemotherapeutic nanomedicines: Polymers and liposomes for delivery of camptothecins and platinum (II) drugs'. Together they form a unique fingerprint.

Cite this